ArticleOdontology2026
DFDBA plus T-PRF with and without vitamin D3 gel in intrabony defects: a randomized controlled trial.
Article in Odontology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Effective periodontal therapy has increasingly focused on the resolution of periodontal defects through a range of regenerative approaches. This study aimed to assess and compare the effectiveness of DFDBA plus T-PRF with and without Vitamin D3 (Vit D3) gel in the treatment of intrabony periodontal defects. Thirty patients with stage III Grade B periodontitis patients having bilateral intrabony defects were involved in the split mouth randomized controlled trial. Defects were treated with DFDBA plus T-PRF (Group I) or DFDBA plus T-PRF with Vit D3 gel (Group II). At baseline, 6 and 12 months, clinical parameters of plaque index (PI), gingival index (GI), probing pocket depth (PPD) and clinical attachment level (CAL) were assessed. CBCT was used to measure the bone defect height (BDH), vertical bone loss (VBL), bone defect depth (BDD), mesio-distal bone defect width (MDBDW), bucco-lingual bone defect width (BLBDW), and bone defect volume (BDV) at baseline and 12 months. Greater reduction in BDD was observed in Group II (3.03 ± 1.68 mm to 1.84 ± 0.75 mm) and Group I (3.84 ± 2.20 mm to 2.51 ± 1.63 mm) (p = 0.045). BLBDW reduction was significantly higher in Group II (2.85 mm) versus Group I (1.80 mm) (p = 0.003). BDH (p = 0.117), VBL (p = 0.067), MDBDW (p = 0.071), and BDV (p = 0.689) were not statistically significant between groups. Vit D3 gel in combination with DFDBA plus T-PRF resulted in improved bone regenerative outcomes when compared to DFDBA plus T-PRF alone. (CTRI/2023/06/053940 [Registered on: 16/06/2023]).
Indexed as
Identifiers
42474918What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.